Saturday, September 19, 2015


- car insurance quotes - For the first time, a widely used modern diabetes drug has been shown to reduce deaths from cardiovascular disease, a long-sought goal of treatment, researchers announced on Thursday.- car insurance companies -

- the general car insurance - In a clinical trial, the drug — Jardiance, sold jointly by Eli Lilly and Boehringer Ingelheim — reduced the overall risk of having a heart attack or stroke, or of dying from cardiovascular causes, by 14 percent. Looking only at cardiovascular deaths, the reduction was 38 percent.

“There are very few therapies we have in cardiovascular medicine that have ever shown a one-third reduction in the risk of cardiovascular death,” said Dr. Steven E. Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, who was not involved in the study.

Because cardiovascular disease is the leading cause of death for people with diabetes, he said, reducing that rate “by 38 percent is a landmark result.”

- general insurance - Still, there were some questions about the data. The drug did not reduce the risk of heart attacks over all by a statistically significant amount, and it actually seemed to raise the risk of stroke, though not by a statistically significant amount. So how did it reduce deaths from cardiovascular causes? One way, not necessarily expected, was by reducing deaths from heart failure, a condition in which the heart cannot pump enough blood.- nvidia drivers -

- cheap car insurance - Lilly and Boehringer announced last month that the drug had decreased cardiovascular problems among trial participants. But the data was not revealed until Thursday, when it was presented in Stockholm at the annual meeting of the European Association for the Study of Diabetes and also published by The New England Journal of Medicine.

Tim Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, tripled his estimate of Jardiance sales in 2020 to $ 2.7 billion. Sales of two other drugs in the same class, known as SGLT2 inhibitors, might also increase even though there is no data yet showing that they decrease cardiovascular risk.

Those drugs are Invokana from Johnson & Johnson and Farxiga from AstraZeneca. The findings could hurt sales of some other types of diabetes drugs, including the Merck blockbuster Januvia. Lilly’s shares rose nearly 7 percent Thursday, to $ 89.98. Boehringer is privately held.

The Food and Drug Administration approves diabetes drugs if they reduce blood sugar levels. It does not require that the drugs be shown to reduce the risks of the complications of high blood sugar, such as heart attacks, even though that is the real goal of treatment.

“The F.D.A. has given diabetes drugs a bye,” said Dr. David M. Nathan, director of the diabetes center at Massachusetts General Hospital. That is because some studies started decades ago suggested that controlling blood sugar did lower the risk of certain complications, like blindness and kidney disease.

But whether the drugs reduce heart attacks and other cardiovascular problems has been less clear. There was some evidence of benefit in the very long run shown in those early studies. But there have also been counterexamples, including one trial several years ago in which more intensive glucose control raised the risk of death.

(Source by:

No comments: